Physicians' Academy for Cardiovascular Education

EASD 2022

News from the hybrid EASD 2022 congress, 19 - 23 Sept - online and in Stockholm, Sweden.

2022 ADA/EASD consensus report on management of hyperglycemia in T2DM

3' education - Sep. 29, 2022 - Prof. John Buse, MD, PhD
What are the most important updates in the 2022 ADA/EASD consensus statement on management of hyperglycemia in patients with T2DM? Prof. Buse -member of the consensus committee- gives a brief overview.

EASD 2022 What are the most important updates in the 2022 ADA/EASD consensus statement on management of hyperglycemia in patients with T2DM? Prof. Buse -member of the consensus committee- gives a brief overview.

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.

Reduced muscle fat infiltration in anterior thigh muscle with GLP-1RA in overweight or obesity

News - Sep. 22, 2022

EASD 2022 A prespecified secondary analysis was performed to investigate whether muscle fat infiltration -associated with increased risk of HF- can be modified by treatment with liraglutide in patients with overweight or obesity.

Effect of SGLT2i on shifts in KDIGO CKD risk groups in T2DM patients

News - Sep. 22, 2022

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.

More remission and less development of metabolic syndrome with GLP-1RA

News - Sep. 21, 2022

EASD 2022 A post hoc analysis of the STEP 5 trial showed that a greater proportion of adults with overweight achieved remission of metabolic syndrome and a smaller proportion developed metabolic syndrome with semaglutide vs. placebo.

Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i

3' education - Sep. 21, 2022 - Marta Seghieri, MD
It is useful to know whether sodium and protein intake affect the early GFR dip that may be observed after initiation with SGLT2i, says Marta Seghieri. She shares the findings of a pilot study.

EASD 2022 It is useful to know whether sodium and protein intake affect the early GFR dip that may be observed after initiation with SGLT2i, says Marta Seghieri. She shares the findings of a pilot study.

Pilot study suggests association of sodium and protein intake with early GFR dip after SGLT2i initiation

News - Sep. 21, 2022

EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD
**EASD 2022** A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

GLP-1RA consistently reduces risk of MACE across kidney function subgroups

News - Sep. 21, 2022

EASD 2022 This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that that semaglutide consistently reduced the risk of MACE across eGFR and UACR subgroups in patients with T2DM who are at high CV risk.

Relationships of CRP and C-peptide with CV events and all-cause mortality in new onset T2DM

News - Sep. 21, 2022

EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.